Roivant Sciences Ltd (ROIV)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 18 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Uses AIRoivant setzt maschinelles Lernen und KI operativ in der Wirkstoffforschung seiner frühen Discovery-Vants und Health-Tech-Töchter ein, verkauft aber keine KI-Produkte.
View the full file — quotes, sources, reviewed filings
„We and certain of our early-stage discovery Vants and healthcare technology businesses use machine learning and AI as part of our business."
Wir und einige unserer frühphasigen Discovery-Vants sowie Gesundheitstechnologie-Geschäfte setzen maschinelles Lernen und KI als Teil unseres Geschäfts ein.
„These risks are of particular relevance to our drug discovery activities, where compromised AI models could undermine target identification, compound screening or other critical research processes."
Diese Risiken sind für unsere Wirkstoffforschung von besonderer Bedeutung, wo beeinträchtigte KI-Modelle die Zielstruktur-Identifikation, das Substanz-Screening oder andere kritische Forschungsprozesse untergraben könnten.
„We believe we are able to develop transformative medicines faster by building and applying computational tools to drug discovery, development and commercialization. We occupy a unique position at the intersection of biopharma and technology."
Wir glauben, transformative Medikamente schneller entwickeln zu können, indem wir rechnergestützte Werkzeuge für Wirkstoffforschung, Entwicklung und Vermarktung bauen und einsetzen. Wir nehmen eine einzigartige Position an der Schnittstelle von Biopharma und Technologie ein.
Filings Reviewed: 10-K 2026-05-20 · 10-K 2025-05-29 · 10-Q 2026-02-06 · 10-Q 2025-11-10 · 10-Q 2025-08-11 · 10-Q 2025-02-10
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.23 | -96.10 | 9 | -42.10 | 1,878.30 | -207 | -209 |
| 2025: Q1 | -0.29 | – | 8 | -73.80 | -2,727.50 | -173 | -173 |
| 2025: Q2 | -0.33 | – | 2 | -51.50 | -10,292.90 | -204 | -208 |
| 2025: Q3 | -0.17 | – | 2 | -64.90 | -7,225.90 | -186 | -194 |
| 2025: Q4 | -0.38 | -262.80 | 2 | -77.80 | -13,301.20 | -197 | -192 |
| 2026: Q1 | 0.37 | – | 3 | -66.70 | 12,023.60 | -164 | -165 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Roivant Sciences Ltd. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entdeckung, Entwicklung und Kommerzialisierung von Medikamenten und Technologien konzentriert.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 721 |
| Headquarters | London, United Kingdom |
| Website | roivant.com |
| IPO Date | 1. Oct 2021 |
| Next Earnings | 10. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Matthew Gline | CEO & Director | 1984 |
| Eric Venker M.D., Pharm.D. | President & CEO of Immunovant | 1987 |
| Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 1976 |
| Richard Pulik | Chief Financial Officer | 1980 |
| Jennifer Humes | Chief Accounting Officer | 1982 |
| Frank M. Torti M.B.A., M.D. | President & Vant Chair | 1979 |
| Huafeng Xu Ph.D. | Chief Technology Officer | – |
| Ian Rosenblum | Chief Information Officer | – |
| Josh Chen J.D. | General Counsel | – |
| Kelly Graff | Head of People | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.